scholarly journals Treatment Options for T1 Stage Adenocarcinoma of Esophagogastric Junction: A Real-World Retrospective Cohort Study

2021 ◽  
Vol 28 ◽  
pp. 107327482110639
Author(s):  
Xiaoying Zhou ◽  
Han Chen ◽  
Shuo Li ◽  
Jie Hua ◽  
Weifeng Zhang ◽  
...  
Keyword(s):  
Esophagogastric Junction ◽  
Treatment Options ◽  
Nodal Status ◽  
Term Survival ◽  
Long Term Survival ◽  
Risk Of Death ◽  
Adenocarcinoma Of Esophagogastric Junction ◽  
Positive Nodal Status ◽  
T1 Stage

Background The number of patients diagnosed with T1 stage adenocarcinoma of esophagogastric junction (AEGJ) has been increasing. This study was conducted to investigate the effect of different treatment options (surgery, chemoradiation, and surgery+chemoradiation) on long-term survival in patients with T1-stage AEGJ. Methods We searched the Surveillance, Epidemiology, and End Results (SEER) database to identify the records of patients with T1-stage AEGJ between 2010 and 2018. Patient demographics and cancer parameters were compared among the three groups. The Kaplan–Meier method and Cox proportional hazard modeling were used to compare long-term survival. Results Data from 925 T1 stage AEGJ patients (surgery: n=516, surgery+chemoradiation: n=206, chemoradiation: n=203) were collected. We found that the OS and CSS rates of three treatment options had significant difference. Besides, positive nodal status also showed lower OS and CSS rat. Multivariate Cox regression analysis showed that surgery group has much lower risk of death compared with chemoradiation group and similar risk of death compared with surgery+chemoradiation group. Subgroup analysis suggested that in patients with N1–N3 status had higher OS and CSS rates in surgery+chemoradiation group. Conclusion Using SEER data, we identified a significant survival advantage with the use of surgery compared to chemoradiation in patients with T1-stage AEGJ while the long-term survival of patients after surgery+chemoradiation group was not significantly different and low risk of death in positive nodal status.

Long-term survival in small-cell carcinoma of the lung: a population experience.

1985 ◽  
Vol 3 (1) ◽  
pp. 80-91 ◽  
Author(s):  
S Davis ◽  
P W Wright ◽  
S F Schulman ◽  
D Scholes ◽  
D Thorning ◽  
...  
Keyword(s):  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Primary Site ◽  
Histologic Type ◽  
Term Survival ◽  
Cell Lung Carcinoma ◽  
Long Term Survival ◽  
Risk Of Death ◽  
Incident Cases

Small-cell lung carcinoma (SCLC) is a rapidly progressive and fatal disease. Historically, surgical resection or radiotherapy of the primary tumor has done little to prolong survival, although the use of combination chemotherapy is more effective. Reported here is the survival experience of 1,538 incident cases of SCLC identified through the Surveillance, Epidemiology and End Results Program in western Washington State from 1974 to 1982. The survival experience of this population series is similar to that reported from specialized referral centers. For 71 of 78 persons surviving at least 24 months, the original diagnostic slides were independently reviewed, 47 cases being confirmed as SCLC. No differences were found in actuarial survival estimates between those confirmed and those not confirmed as SCLC. Multivariate survival analysis was conducted to estimate the effects on survival of stage, therapy, age, sex, primary site, and histologic type. All factors except primary site and histologic type significantly influence initial survival rates. However, the only factor related to post--two-year (ie, long-term) survival, once stage is accounted for, is whether surgery was received as a first course of therapy. Those not receiving surgery were at four times the risk of death as those who did. These results indicate that long-term survival can be achieved in patients with SCLC treated in the community, and that the chance of surviving an additional two years for such patients is approximately 40%.

Adrenal metastases from adenocarcinoma of the esophagogastric junction: adrenalectomy and long-term survival

2010 ◽  
Vol 62 (1) ◽  
pp. 63-67 ◽  
Author(s):  
Uberto Fumagalli ◽  
Stefano de Carli ◽  
Stefano de Pascale ◽  
Lorenza Rimassa ◽  
Mario Bignardi ◽  
...  
Keyword(s):  
Esophagogastric Junction ◽  
Adrenal Metastases ◽  
Term Survival ◽  
Long Term Survival

Long-term survival after multidisciplinary treatments for advanced esophagogastric junction cancer

2021 ◽  
Author(s):  
Chihiro Matsumoto ◽  
Masaaki Iwatsuki ◽  
Takeshi Morinaga ◽  
Kohei Yamashita ◽  
Kenichi Nakamura ◽  
...  
Keyword(s):  
Esophagogastric Junction ◽  
Term Survival ◽  
Long Term Survival ◽  
Esophagogastric Junction Cancer

scholarly journals Reoperation for bleeding in an elective cardiac surgical population - Does it affect survival?

2021 ◽  
Vol 13 (3) ◽  
pp. 198-202
Author(s):  
Saddiq Mohammad Qazi ◽  
Kristian Kandler ◽  
Peter Skov Olsen
Keyword(s):  
Cardiac Surgery ◽  
Cox Regression ◽  
University Hospital ◽  
Term Survival ◽  
Long Term Survival ◽  
Cox Regression Analysis ◽  
Risk Of Death ◽  
Short And Long Term ◽  
Elective Patients

Introduction: Earlier studies have shown that re-operation for bleeding after cardiac surgery is associated with increased mortality and morbidity in both acute and elective patients. The aim of the study was to assess the effect of re-operation for bleeding on short- and long-term survival and the causes of re-operation on an exclusively elective population. Methods: This was a single-center, retrospective study conducted at the Department of Cardiothoracic Surgery at Copenhagen University Hospital. Rigshospitalet, Denmark. We included all elective patients undergoing first-time coronary bypass, valve surgery or combinations hereof between January 1998 and February 2014. Data was obtained from the electronic patient records on demographics, cardiological risk profile, blood transfusion and surgical record. Results: A total of 11813 patients were included in the analysis of whom 626 (5.3%) patients underwent re-operation for bleeding. Patients were divided into two groups; non re-operated (NRO) and re-operated(RO). Baseline characteristics were comparable. Median survival was lover in the RO group (142 vs 160months (P = 0.001)). Morbidity and 30 day mortality was significantly higher in the RO group. Cox-regression analysis showed a significantly increased age-adjusted risk of death in the RO group (HR 1.21(1.07-1.37). P = 0.003). In 85% of the patients the site of bleeding was found during the re-operation. Conclusion: We found both short and long-term survival to be lower in the RO group. A surgical cause for re-operation was found in the majority of cases. The study shows the importance of meticulous hemostasis during cardiac surgery.

Long-Term Survival, Causes of Death, and Trends in 5-Year Mortality After Intracerebral Hemorrhage: The Tromsø Study

Stroke ◽  
2021 ◽  
Author(s):  
Maria Carlsson ◽  
Tom Wilsgaard ◽  
Stein Harald Johnsen ◽  
Liv-Hege Johnsen ◽  
Maja-Lisa Løchen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Intracerebral Hemorrhage ◽  
Causes Of Death ◽  
Population Based ◽  
Term Survival ◽  
Long Term Survival ◽  
Risk Of Death ◽  
Increased Risk

Background and Purpose: Data on long-term survival after intracerebral hemorrhage (ICH) are scarce. In a population-based nested case-control study, we compared long-term survival and causes of death within 5 years in 30-day survivors of first-ever ICH and controls, assessed the impact of cardiovascular risk factors on 5-year mortality, and analyzed time trend in 5-year mortality in ICH patients over 2 decades. Methods: We included 219 participants from the population-based Tromsø Study, who after the baseline participation had a first-ever ICH between 1994 to 2013 and 1095 age- and sex-matched participants without ICH. Cumulative survival was presented using the Kaplan-Meier method. Hazard ratios (HRs) for mortality and for the association between cardiovascular risk factors and 5-year mortality in 30-day survivors were estimated by stratified Cox proportional hazards models. Trend in 5-year mortality was assessed by logistic regression. Results: Risk of death during follow-up (median time, 4.8 years) was increased in the ICH group compared with controls (HR, 1.62 [95% CI, 1.27–2.06]). Cardiovascular disease was the leading cause of death, with a higher proportion in ICH patients (22.9% versus 9.0%; P <0.001). Smoking increased the risk of 5-year mortality in cases and controls (HR, 1.59 [95% CI, 1.15–2.19]), whereas serum cholesterol was associated with 5-year mortality in cases only (HR, 1.39 [95% CI, 1.04–1.86]). Use of anticoagulants at ICH onset increased the risk of death (HR, 2.09 [95% CI, 1.09–4.00]). There was no difference according to ICH location (HR, 1.15 [95% CI, 0.56–2.37]). Five-year mortality did not change during the study period (odds ratio per calendar year, 1.01 [95% CI, 0.93–1.09]). Conclusions: Survival rates were significantly lower in cases than in controls, driven by a 2-fold increased risk of cardiovascular death. Smoking, serum cholesterol, and use of anticoagulant drugs were associated with increased risk of death in ICH patients. Five-year mortality rates in ICH patients remained stable over time.

Long-term Survival in the Intensive Care Unit After Erythrocyte Blood Transfusion

2009 ◽  
Vol 18 (2) ◽  
pp. 124-131 ◽  
Author(s):  
Milo Engoren ◽  
Cynthia Arslanian-Engoren
Keyword(s):  
Intensive Care ◽  
Blood Transfusion ◽  
Confidence Interval ◽  
Intensive Care Units ◽  
Case Control ◽  
Apache Ii ◽  
Term Survival ◽  
Long Term Survival ◽  
Risk Of Death

Background Erythrocyte blood transfusions are commonly used in intensive care units, yet little is known about their effects on long-term survival. Objective To determine the effect of erythrocyte blood transfusion in intensive care units on long-term survival. Methods Retrospective analysis of a prospectively collected database of 2213 patients admitted January 27, 2001, to April 30, 2002, to the cardiac, burn, neurological-neurosurgical, and combined medical-surgical intensive care units in a tertiary care, university-affiliated, urban medical center. Further analysis was done on a case-control subgroup (n = 556) formed by matching scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II and propensity scores. Results Although transfusion was univariably associated with increased risk of death at all 3 times (0–30, 31–180, and &gt;180 days after admission to the unit), multivariable adjustment with Cox modeling showed that transfusion had no association with mortality for the first 2 intervals (0–30 and 31–180 days), but was associated with a 25% lower risk of death (hazard ratio, 0.75; 95% confidence interval, 0.57–0.99; P = .04) in patients who survived at least 180 days after admission to the unit. In the case-control patients, after correction for APACHE II risk of death and propensity to receive a transfusion, transfusion had no association with mortality for the first 2 intervals, but was associated with 29% lowered risk of death (hazard ratio, 0.71; 95% confidence interval, 0.50–0.99; P=.046). Conclusion Blood transfusion was associated with a decreased risk of late (&gt;180 days) death in intensive care patients.

Sign in / Sign up

Export Citation Format

Share Document